Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004478485 | SCV004981902 | uncertain significance | not specified | 2023-10-13 | criteria provided, single submitter | clinical testing | The c.283T>G (p.L95V) alteration is located in exon 3 (coding exon 3) of the YME1L1 gene. This alteration results from a T to G substitution at nucleotide position 283, causing the leucine (L) at amino acid position 95 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005104777 | SCV005768832 | uncertain significance | not provided | 2024-05-18 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 95 of the YME1L1 protein (p.Leu95Val). This variant is present in population databases (rs774202908, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with YME1L1-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |